Charlotte Gaskell

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe et al. · Nature Medicine · 2023 · 124 citations · Full text

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Jennifer Pascoe, Aimee Jackson, Charlotte Gaskell et al. · BMC Cancer · 2021 · 97 citations · Full text

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)

Jennifer Pascoe, Aimee E. Houlton, Charlotte Gaskell et al. · Research Square (Research Square) · 2021 · 78 citations · Full text

Cancer Management, Pharmacotherapy, Beta-hydroxy Beta-methylbutyrate/arginine/glutamine +16

Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial

Pamela Kearns, Stefan Siebert, Michelle Willicombe et al. · SSRN Electronic Journal · 2021 · 74 citations · Full text

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Tonny Veenith, Daniel Slade, Charlotte Gaskell et al. · UCL Discovery (University College London) · 2022 · 57 citations

Disease Management, Proof-of-concept Trial, Symptomatic Treatment +7